AG真人官方

Form 4 shows President & CEO Christopher Hufnagel executed routine equity transactions in Wolverine World Wide (WWW) on 31 Jul 2025. He converted 13,154 restricted stock units (code M) into common shares at no cash cost, as RSUs convert 1-for-1. To satisfy tax-withholding obligations he disposed of 5,703 shares (code F) at $22.58 per share. Net of the withholding, Hufnagel added 7,451 shares to his direct holdings.

After the transactions, the CEO directly owns 231,558 common shares and retains 13,155 unvested RSUs from the July 2023 grant that vests in equal thirds through 2026. No derivative securities were sold for cash consideration. The filing indicates continued equity alignment by the CEO rather than an open-market sale, and does not alter control percentages or signal any change in corporate outlook.

Form 8-K filed 4 Aug 2025: Olo Inc. furnished Item 2.02, attaching Exhibit 99.1 that contains its financial results for the quarter ended 30 Jun 2025. The press release is treated as 鈥渇urnished,鈥� not 鈥渇iled,鈥� limiting Exchange Act liability.

The report also highlights a pending merger between Olo and Project Hospitality Parent, LLC, to be executed via Project Hospitality Merger Sub, Inc. A preliminary proxy statement was submitted on 28 Jul 2025; a definitive proxy will be mailed to stockholders once available. Investors are urged to read these materials because they will include important information about the transaction and participants in the solicitation.

No financial tables, pro-forma data or merger terms are included in this filing. Exhibits: 99.1 (press release) and 104 (cover-page inline XBRL).

Hims & Hers Health, Inc. (HIMS) 鈥� Form 144 filing discloses an insider鈥檚 intention to sell 250 Class A shares (estimated market value $16,110) on or after 1 Aug 2025 through Fidelity Brokerage on the NYSE. The notice also details recent insider activity: over the past three months the same individual, Michael Y. Chi, has already sold 69,802 Class A shares for gross proceeds of 鈮�$4.27 million. Outstanding Class A shares total 215.45 million, so the planned sale represents a negligible 0.0001% of shares outstanding, while the cumulative three-month sales equal roughly 0.03%.

The signer affirms he is unaware of any undisclosed material adverse information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No other financial metrics, guidance, or operational updates are provided; the filing is strictly a procedural notice under Rule 144.

Hims & Hers Health, Inc. (HIMS) 鈥� Form 144 filing

Insider Michael Y. Chi has filed a notice to sell 26,350 Class A shares through Fidelity Brokerage on or about 31 Jul 2025 on the NYSE. At the 07/30/25 market price used by the filer, the stake is valued at $1.77 million and represents roughly 0.012 % of the company鈥檚 215.45 million shares outstanding.

The shares were acquired via four employee option grants dated 24 Feb 2022, 27 May 2021, 10 Aug 2022 and 01 Mar 2023, all exercised for cash on 31 Jul 2025. Over the past three months Chi has already disposed of 43,452 shares in five open-market transactions between 06 Jun 2025 and 24 Jul 2025, generating $2.51 million in gross proceeds.

No additional financial data, earnings guidance or company commentary is included in this notice. The filing merely discloses the planned sale under Rule 144 and affirms that the filer is not in possession of undisclosed material adverse information.

Keurig Dr Pepper Inc. (KDP) filed a Form 144 indicating that the Robert J. Gamgort 1999 Trust intends to sell 208,000 common shares through Morgan Stanley Smith Barney on or about 29 Jul 2025. At an assumed market price of roughly $32.95 per share, the aggregate value is $6.86 million. KDP has 鈮�1.36 billion shares outstanding, so the proposed sale represents 鈮�0.015 % of total shares.

The trust鈥攁ssociated with KDP鈥檚 Executive Chairman Robert Gamgort鈥攈as already executed two sales under a Rule 10b5-1 trading plan within the past three months:

• 1 May 2025: 208,000 shares for $7.10 million
• 2 Jun 2025: 208,000 shares for $6.89 million

No purchase-price debt, material adverse information, or non-public information is indicated, and the filer affirms compliance with Rule 144 and 10b5-1 requirements. While the dollar amount is notable, the percentage of float is immaterial and does not, by itself, signal a shift in company fundamentals.

Hims & Hers Health, Inc. (HIMS) filed a Form 144 indicating that stockholder Soleil Boughton intends to sell 2,572 Class A shares through Fidelity Brokerage on or about 07/28/2025 on the NYSE. The proposed sale has an aggregate market value of $150,976.40, based on data supplied in the filing. Shares outstanding are listed at 215,453,899, so the contemplated sale represents roughly 0.0012 % of total Class A shares.

The shares to be sold were acquired via restricted-stock vesting on 06/15/2025 and are being sold for compensation purposes. The filer certifies possession of no undisclosed material adverse information.

Recent activity: Over the past three months, the same seller disposed of 22,871 shares across seven transactions, generating $1.18 million in gross proceeds. Transaction sizes ranged from 2,572 to 5,451 shares, signalling a pattern of periodic liquidations rather than a single block sale.

No other financial metrics, earnings data, or company-level events are disclosed in this notice.

Hims & Hers Health (HIMS) Form 4: Chief Commercial Officer Michael Chi executed and sold option shares on 23-24 Jul 2025 under a Rule 10b5-1 plan adopted 4 Mar 2025.

• Option exercises: 15,850 Class A shares exercised at strike prices of $5.01, $6.82 and $11.53.
• Sales: 15,850 shares sold almost immediately at weighted prices of ~$56鈥�57.52, realising a gross spread of >$45 per share.
• Post-trade holdings: Direct ownership remains 278,654 shares. Derivative holdings (vested/unvested options) fall to 192,942.
• Options stem from 2022-23 grants that vest monthly over four years; earliest expiry 24 Feb 2032.

No change to total common stock held, but the executive monetised ~6% of his prior common share position while retaining a sizeable stake and option pool.

The Form 144 filing indicates that an insider, Michael Y. Chi, plans to sell up to 2,100 Class A shares of Hims & Hers Health, Inc. (HIMS) through Fidelity Brokerage on or about 24 Jul 2025. At the prevailing price used in the form, the proposed sale is valued at $120,792. With 215,453,899 Class A shares outstanding, the transaction represents roughly 0.001 % of the public float.

Chi acquired the shares via an employee stock option granted 24 Feb 2022 and exercised for cash on 24 Jul 2025. The filing also discloses prior insider activity:

• 5100 shares sold 06 Jun 2025 for $285,600
• 5400 shares sold 10 Jun 2025 for $307,800
• 17,102 shares sold 17 Jun 2025 for $1,021,844.50
• 13,750 shares sold 23 Jul 2025 for $770,000

The notice affirms the seller is not aware of undisclosed adverse information. While continued insider selling may warrant monitoring, the volume remains immaterial relative to the company鈥檚 capitalization and is unlikely to affect trading dynamics on its own.

Nature's Sunshine Products (NATR) 鈥� Insider Form 4

EVP & General Counsel Nathan G. Brower reported an automatic share withholding on 21 Jul 2025. The filing (Transaction Code F) shows 1,491 common shares withheld at $14.80 to cover taxes triggered by the vesting of restricted stock units granted on 21 Jul 2022. After the transaction, Brower directly owns 58,273 NATR shares. Because Code F represents a tax-payment mechanism rather than an open-market trade, the executive鈥檚 net economic exposure to the company remains essentially unchanged.